Atossa Therapeutics (NASDAQ:ATOS) Upgraded by StockNews.com to “Hold”

Atossa Therapeutics (NASDAQ:ATOS) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.

A number of other research analysts also recently commented on the company. Ascendiant Capital Markets upped their price objective on Atossa Therapeutics from $6.25 to $6.50 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of Atossa Therapeutics in a research report on Monday, August 12th.

Atossa Therapeutics Price Performance

NASDAQ ATOS opened at $1.42 on Friday. The company has a market capitalization of $178.57 million, a price-to-earnings ratio of -5.92 and a beta of 1.20. Atossa Therapeutics has a 12 month low of $0.62 and a 12 month high of $2.31. The company’s fifty day moving average price is $1.42 and its two-hundred day moving average price is $1.39.

Atossa Therapeutics (NASDAQ:ATOS) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. As a group, analysts anticipate that Atossa Therapeutics will post -0.22 EPS for the current year.

Hedge Funds Weigh In On Atossa Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ATOS. XTX Topco Ltd bought a new stake in shares of Atossa Therapeutics in the 2nd quarter worth $29,000. SG Americas Securities LLC grew its holdings in Atossa Therapeutics by 254.3% during the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock worth $64,000 after acquiring an additional 30,037 shares during the period. Cetera Advisors LLC bought a new stake in Atossa Therapeutics in the first quarter worth about $72,000. Virtu Financial LLC acquired a new stake in Atossa Therapeutics in the 1st quarter valued at about $151,000. Finally, Rhumbline Advisers bought a new position in shares of Atossa Therapeutics during the 2nd quarter valued at about $161,000. 12.74% of the stock is owned by institutional investors.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.